Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (4891)	7/19/1998 10:00:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Fauci is a very good scientist. I first met him at a poster presentation at FASEB, Anaheim, 1976. We were presenting at adjacent posters (Fed. Proc. 35: 312, 1976). He was impressive as an unknown, and he's impressive now that he's famous. He's correct..... we don't know the ultimate impact of multiple resistance. So.... we go back to the same place..... I find all of this anxiety, lying and short-selling to be somewhat humorous....... Viracept is the PI of choice for most patients. One can confidently ignore DMP-266 and protease replacement. One can confidently ignore rit/crix combinations. Viracept is an enormously valuable property. Bhag.... AGPH has presented data that clearly differentiates 3340 from Marimastat, showing Col-1/Gel A selectivity ratios of 150 for 3340 and 0.3 for Marimastat. They show 3340 to be 63 fold more effective at inhibiting stromelysin-1 and 20-fold more effective at inhibiting gelatinase-A. In contrast, 3340 is relatively inactive on collagenase-1 and matrilysin. The structures of 3340 and marimastat are very different.